![Kevin HARRINGTON | Institute of Cancer Research, London | Division of Radiotherapy and Imaging | Research profile Kevin HARRINGTON | Institute of Cancer Research, London | Division of Radiotherapy and Imaging | Research profile](https://i1.rgstatic.net/ii/profile.image/556535446872065-1509699798223_Q512/Kevin-Harrington-2.jpg)
Kevin HARRINGTON | Institute of Cancer Research, London | Division of Radiotherapy and Imaging | Research profile
![Kevin HARRINGTON | Institute of Cancer Research, London | Division of Radiotherapy and Imaging | Research profile Kevin HARRINGTON | Institute of Cancer Research, London | Division of Radiotherapy and Imaging | Research profile](https://www.researchgate.net/publication/359388167/figure/fig1/AS:1138994456870913@1648568848067/ATRi-potentiates-RT-mediated-antitumor-immune-response-A-Experimental-design-for-the_Q320.jpg)
Kevin HARRINGTON | Institute of Cancer Research, London | Division of Radiotherapy and Imaging | Research profile
![Amazon | Targeted Therapy for Cancer (Medicine) | Syrigos, Konstantinos N., Harrington, Kevin | Oncology Amazon | Targeted Therapy for Cancer (Medicine) | Syrigos, Konstantinos N., Harrington, Kevin | Oncology](https://m.media-amazon.com/images/I/51QTEJSRAGL._SX360_BO1,204,203,200_.jpg)
Amazon | Targeted Therapy for Cancer (Medicine) | Syrigos, Konstantinos N., Harrington, Kevin | Oncology
ESMO Immuno-Oncology Virtual Congress 2020 | #ESMOImmuno20 Virtual Congress: Prof. Kevin Harrington, Scientific Co-Chair, tells you why this event is so unique. Remember that ESMO Members register... | By ESMO - European
![Immunotherapy for recurrent or metastatic HNSCC: What are the practical considerations? - touchONCOLOGY Immunotherapy for recurrent or metastatic HNSCC: What are the practical considerations? - touchONCOLOGY](https://embed-ssl.wistia.com/deliveries/a43b9d4a477e79a284fe2ef2d33f001b.jpg?image_crop_resized=640x360)
Immunotherapy for recurrent or metastatic HNSCC: What are the practical considerations? - touchONCOLOGY
![Clinical results, patient cases and future developments II: Head & neck cancer – Kevin Harrington on Vimeo Clinical results, patient cases and future developments II: Head & neck cancer – Kevin Harrington on Vimeo](https://i.vimeocdn.com/filter/overlay?src0=https%3A%2F%2Fi.vimeocdn.com%2Fvideo%2F721395685-103bfcddfe6c239bc7e0e55bebd0924d2cb62b4d6b9033060d1f15df72cdd23c-d_1280x720&src1=https%3A%2F%2Ff.vimeocdn.com%2Fimages_v6%2Fshare%2Fplay_icon_overlay.png)
Clinical results, patient cases and future developments II: Head & neck cancer – Kevin Harrington on Vimeo
![World's first centre for recurrent head and neck cancer launched - Professor Christopher Nutting Oncology World's first centre for recurrent head and neck cancer launched - Professor Christopher Nutting Oncology](https://www.chrisnutting-oncology.co.uk/cms/wp-content/uploads/2022/01/royalmarsden_67975358223_0-500x333.jpeg)
World's first centre for recurrent head and neck cancer launched - Professor Christopher Nutting Oncology
![Kevin Harrington, The Original Shark from Shark Tank and Inventor of The Infomercial Joins the Advisory Board of USARAD including its SecondOpinions.com® Division Kevin Harrington, The Original Shark from Shark Tank and Inventor of The Infomercial Joins the Advisory Board of USARAD including its SecondOpinions.com® Division](http://ww1.prweb.com/prfiles/2021/01/11/17654673/Kevin%20Harrington%200159%20AAA%202.jpeg)